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S210 Poster Session Iweeks after adoptive transfer, AML in bone marrow (BM) of
PR1-CTL treated mice decreased 27% (range 21%-32%; p \
0.02) compared to untreated mice, and by 23% (range 4%-47%; p
5 NS) compared to mice receiving PDC. Moreover, AML in the
PB of PR1-CTL treated mice decreased 47% (range 30%-61%, p
\ 0.04) compared to untreated mice, and by 58% (range 48%-
68%; p\0.01) compared to mice receiving PDC. These data justify
clinical studies to determine whether PR1-CTL isolated directly
from UCB can be used to enhance GVL without increased GVHD.153
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Background: Allogeneic natural killer (NK) cells are active in vari-
ous hematologic malignancies and may have an important role in
multiple myeloma (MM). Umbilical cord blood (UCB) is a potential
source for allogeneic NK cells and ex vivo expanded UCB-derived
NK (UCB-NK) cells demonstrate activity comparable to that of pe-
ripheral blood-derived NK cells. Here we demonstrate the ability to
expand fresh and frozen UCB-NK cells to clinical grade by novel
techniques using artificial antigen presenting feeder cells modified
to express IL-21 (‘‘K562-cl9-mIL21’’) or IL-15 (‘‘K562-mb-15-
41BBL’’). TheseUCB-NK cells demonstrate appropriate phenotype
and are active against a variety of MM cell lines.
Methods: UCB-NK cells were expanded from 1) fresh or 2) frozen
cord blood units. 1) Fresh cord blood mononuclear cells (CBMCs)
were cultured in 10% human serum albumin media with IL-2 (500
IU/ml) and irradiated K562-cl9-mIL21 feeder cells (2:1 feeder:
CBMCratio) for 21 days.Thereafter, cells were subjected toCD3-im-
munomagnetic depletion. 2) Frozen CBMC’s were grown in a gas
permeable culture flask with IL-2 (100 IU/ml) and irradiated K562-
mb-15-41BBL feeder cells (2:1 feeder: CBMC ratio). Cells were
CD3-depleted on day 7, replated with the same conditions and grown
until day 14. CD3-negative cells were then used as effector cells in
functional assays. Flow cytometry was used to confirmNK cell purity
(C561/CD3- cells) and a standard chromium-51 assay was performed
to determine NK cell cytotoxicity. Targets included K562 cells and
MM cell lines RPMI 8226, ARP-1 and U266.
Results:Expansion of fresh and frozenCBMCs yielded a. 2000 and
. 200 fold expansion ofNKcells, respectively, compared with only 47
fold expansion of fresh CD56-selected cells cultured with IL-2 alone.
After CD3 depletion, fresh and frozen-derived UCB-NK cultures
were comprised of 92% and 94% CD561/CD3- cells respectively.
APC-expanded UCB-NK cells from fresh and frozen cords demon-
strated cytotoxicity against the classic NK cell target K562 as well as
MM cell lines RPMI 8226, ARP-1 and U266.
Conclusions: UCB-NK cells can be expanded ex vivo to clinically
relevant doses for allogeneic NK cell therapy via co-culture with
K562-cl9-mIL21 and K562-mb-15-41BBL feeder cells. Expanded
UCB-NK cells are cytotoxic to K562 cells and various myeloma cell
lines.Further studyof freshand frozen-derivedUCB-NKcells asanad-
junct therapy in stem cell transplantation for myeloma is warranted.154
TRANSFER OF SPECIFIC CELLULAR AND HUMORAL ANTI-TUMOR IMMU-
NITY AFTER STEM CELL TRANSPLANT (SCT) BY VACCINATING STAGE IV
BREAST CANCER PATIENTS WITH Her2/Neu TARGETED T CELLS AND
TRANSFERRING IMMUNE T CELLS INTO THE PATIENTS AFTER SCT
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MI; 2College Veterinary Medicine, East Lansing, MI; 3Roger William
Medical Center, Providence, RIWomen with stage IV metastatic breast cancer (BrCa) have lim-
ited treatment options. Innovative treatment strategies are needed
to improve anti-tumor responses. We have recently shown that spe-
cific T cell immunity can be induced in patients by ‘‘vaccinating’’ the
patients (pts) with infusions of anti-CD3  anti-Her2/neu bispecific
antibody (Her2Bi) armed activated T cells (aATC). This study inves-
tigated whether memory cytotoxic T lymphocytes (CTL) and anti-
body (Ab) directed at BrCa antigens can be transferred into
patients after SCT by evaluating the cytotoxic and Ab responses after
aATC infusions prior to SCT and after SCT. After infusions of
aATC, peripheral blood lymphocytes (PBL) exhibited high levels
of cytotoxicity directed at SK-BR-3 breast cancer cells and high se-
rum levels of Th1 cytokines and IL-12. Three weeks after aATC in-
fusions, ATC were expanded from the second leukopheresis and
cryopreserved for re-infusion after SCT. The expanded ATC from
6 patients at an E:T ratio of 25:1 exhibited cytotoxicity ranging
from 3.7-25.8 (mean13.6%) directed at the SK-BR-3. After SCT,
pts received multiple infusions with a mean total of 54x109 ATC
(range 16-110  109). Cytotoxicity ranged from 4.7 to 70 % from
2 weeks to 12 months post SCT. We tested PBL for the transfer
of humoral immunity after SCT by co-culturing PBL with or with-
out SK-BR-3 tumor cells before IT, mid-IT, 1 month post-IT, pre
and post SCT for in vitro specific anti-SK-BR-3 Ab synthesis.
Anti-SK-BR-3 Abs detected in the culture supernatants by ELISA
ranged from 15 to 40 ng/ml of Abs prior to IT, 150-220 ng/ml
mid-IT and remained high between 70-95 ng/ml at 1 month post-
IT. PBL after SCT showed gradual increases in in vitro Ab synthesis
ranging from 0-10 ng at 1-month post SCT to 70-90 ng by six-
month post SCT upon stimulation with tumor cells. Serum antitu-
mor Ab levels directed at SK-BR-3 increased from 2-4 mg to 10-12
mg post IT and between 6-9 mg after SCT. No dose-limiting
toxicities, delays in engraftment, and life-threatening infections
were observed. These data show that transfer of pre-immunized
ATC and T cells in the stem cell product enhance tumor specific cy-
totoxicity after HDC and PBSCT for breast cancer. Data suggest
that both cellular and Ab responses can be transferred and provide
an anti-tumor immune response early after SCT. This ‘‘vaccinate’’
and ‘‘boost’’ proof-of-principal strategy may be used to design
protocols to enhance anti-tumor activity.155
IMPROVED POST-THAW STABILITY VALIDATION OF PERIPHERAL BLOOD
CELL PRODUCTS UTILIZING THE INTRACELLULAR-LIKE CryoStor
CRYOPRESERVATION SOLUTION, AND PRELIMINARY RESULTS OF
CLINICAL APPLICATION
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Collection and cryopreservation of autologous stem cells is a rou-
tine procedure in a variety of malignant diseases. Further, improved
stability of cell products is critical to the development of cell and tis-
sue based therapies as part of the growth in regenerative medicine. A
growing body of evidence indicates that one key method for im-
proved cryopreservation efficacy is the utilization of a hyperos-
motic/intracellular-like cryopreservation media, as opposed to the
traditional use of an isotonic/extracellular-like media such as saline
as the vehicle for the cryoprotectant. In this evaluation of cryopres-
ervationmethods for clinical application, cell samples from apheresis
products were cryopreserved in a conventional isotonic-based freeze
media (CFM; 20% DMSO, 10% human plasma derivate in Ringer
solution) or intracellular-like CryoStor CS10 (CS10; 10% DMSO,
serum-free and protein-free). Immediately after thawing, the recov-
ery ofWBCwas 50.76 14.4% forCFMversus 706 11.6% forCS10
(p\0.001), and that of CD341 cells 81.86 36.1% forCFMand 101
6 16.4% for CS10 (p\ 0.05). In CFM, 20 to 60 min after thawing
there was a dramatic loss in cell viability (-40% to -90%), up to com-
plete clotting in 3/10 samples. By contrast, cells remained viable up
to 60 min after thawing in CS10, and no clotting occurred. Because
of these positive validation results, cryopreservation in the intracel-
lular-like CryoStor CS10 was translated to clinical application for
treatment of hematological malignancies. To date, seven patients
have received autologous stem cells cryopreserved in CS10.
